Felix Laboratory

AddtoAny
Share:

WATCH THIS PAGE

Subscribe to be notified of changes or updates to this page.

2 + 0 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.

The Felix Lab aims to understand the pathobiology of leukemias with KMT2A (mixed-lineage leukemia) translocations to discover better treatments and preventive approaches through molecular, biochemical, cellular and in vivo methods.

These leukemias have a poor prognosis and primarily affect infants and young children or occur as a complication of TOP2 poison chemotherapies. The goal of the research conducted in this laboratory is to develop preventive strategies and less toxic, targeted new treatments for infant leukemias and secondary leukemias that occur as a chemotherapy complication.

Learn More

Leader
Carolyn A. Felix

Carolyn A. Felix, MD

Leader, Normal and Malignant Hematopoiesis Research Affinity Group
Dr. Felix uses molecular, biochemical, cellular and in vivo methods to investigate the pathobiology of leukemias with KMT2A (MLL) translocations. Leukemias with these translocations affect infants and young children or occur as a complication of type II topoisomerase (TOP2) poison chemotherapies used for anti-cancer treatment. She aims to develop better treatment and prevention approaches for these leukemias, which have a poor prognosis.